Efficacy and Safety of Telmisartan 20 mg/S-Amlodipine 2.5 mg versus Telmisartan 40 mg in Patients with Hypertension, Inadequately Controlled on Telmisartan 20 mg Monotherapy: A Randomized, Double-Blind, Multicenter, Phase 3 Trial
Drug Design, Development and Therapy · 2026-05 · Volume 20 · 1-12
DOI: 10.2147/dddt.s587488 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Drug Design, Development and Therapy, 2026-05. Verfasst von Jong-Chan Youn und 13 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiology, Department of Internal Medicine, Seoul St. Mary's Hospital, Catholic Research Institute for Intractable Cardiovascular Diseas…. Hauptthemen laut MEDLINE: Telmisartan, Amlodipine, Hypertension, Antihypertensive Agents. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Cardiology, Department of Internal Medicine, Seoul St. Mary's Hospital, Catholic Research Institute for Intractable Cardiovascular Disease, College of Medicine, The Catholic University of Korea, Seoul, Repub…
- Department of Cardiology, Dong-A University Hospital, Busan, Republic of Korea.
- Division of Cardiology, Department of Internal Medicine, Daegu Catholic University, Daegu, Republic of Korea.
- Department of Cardiology, Cardiovascular Center, Korea University Anam Hospital, Korea University College of Medicine, Seoul, Republic of Korea.
- Division of Cardiology, Department of Internal Medicine, Gyeongsang National University Hospital, Gyeongsang National University School of Medicine, Jinju, Republic of Korea.
- Division of Cardiology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea.
ORCID-Profile: Jong-Chan Youn, Eui-Soon Kim, Young Soo Lee
Zitieren
APA
Youn, J. C., Kim, E. S., Park, T. H., Lee, Y. S., Hong, S. J., Hwang, J. Y., Han, J. K., Son, J. W., Lee, C. J., Choi, J. H., Kwon, S. U., Kim, S. Y., Park, H. C., & Choi, S. H. (2026). Efficacy and Safety of Telmisartan 20 mg/S-Amlodipine 2.5 mg versus Telmisartan 40 mg in Patients with Hypertension, Inadequately Controlled on Telmisartan 20 mg Monotherapy: A Randomized, Double-Blind, Multicenter, Phase 3 Trial. Drug Design, Development and Therapy, Volume 20, 1-12. https://doi.org/10.2147/dddt.s587488
Vancouver
Youn JC, Kim ES, Park TH, Lee YS, Hong SJ, Hwang JY, et al. Efficacy and Safety of Telmisartan 20 mg/S-Amlodipine 2.5 mg versus Telmisartan 40 mg in Patients with Hypertension, Inadequately Controlled on Telmisartan 20 mg Monotherapy: A Randomized, Double-Blind, Multicenter, Phase 3 Trial. Drug Design, Development and Therapy. 2026;Volume 20:1-12. doi:10.2147/dddt.s587488
BibTeX
@article{Youn2026,
author = {Youn, Jong-Chan and Kim, Eui-Soon and Park, Tae Ho and Lee, Young Soo and Hong, Soon Jun and Hwang, Jin-Yong and Han, Jung-Kyu and Son, Jung-Woo and Lee, Chan Joo and Choi, Jung Hyun and Kwon, Sung Uk and Kim, Seok Yeon and Park, Hwan-Cheol and Choi, Seung-Hyuk},
title = {Efficacy and Safety of Telmisartan 20 mg/S-Amlodipine 2.5 mg versus Telmisartan 40 mg in Patients with Hypertension, Inadequately Controlled on Telmisartan 20 mg Monotherapy: A Randomized, Double-Blind, Multicenter, Phase 3 Trial},
journal = {Drug Design, Development and Therapy},
year = {2026},
volume = {Volume 20},
pages = {1--12},
doi = {10.2147/dddt.s587488}
}
EUVIMED